Literature DB >> 20212226

Primary central nervous system lymphoma.

Elizabeth R Gerstner1, Tracy T Batchelor.   

Abstract

Primary central nervous system (CNS) lymphoma (PCNSL), an uncommon variant of extranodal non-Hodgkin lymphoma (NHL), can affect any part of the neuraxis including the eyes, brain, leptomeninges, or spinal cord. It accounts for approximately 3% of all the primary CNS tumors diagnosed each year in the United States. Congenital or acquired immunodeficiency is the only established risk factor for PCNSL, and individuals with human immunodeficiency virus (HIV) infection are at greater risk for developing this tumor. Infection with HIV likely accounted for the increased incidence in PCNSL observed from 1970 to 2000, but over the last decade the number of cases of PCNSL has stabilized or decreased to about 0.47 cases per 100 000 persons. Owing to the rarity of PCNSL, the disease has been challenging to study and an effective standard of care has been difficult to establish. Unfortunately, although durable remissions may be achieved for some patients with PCNSL, the tumor relapses in most cases. In this review, we will focus on PCNSL in the immunocompetent host.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20212226     DOI: 10.1001/archneurol.2010.3

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  46 in total

1.  Neurotropic T-cell-rich B-cell lymphoma in a 14-year-old Morgan gelding.

Authors:  Trina L Westerman; Keith P Poulsen; John W Schlipf; Beth A Valentine
Journal:  Can Vet J       Date:  2014-04       Impact factor: 1.008

Review 2.  Primary central nervous system lymphoma: implication of high-dose chemotherapy followed by auto-SCT.

Authors:  N Reddy; B N Savani
Journal:  Bone Marrow Transplant       Date:  2011-10-17       Impact factor: 5.483

3.  Radiotherapy: has the role of WBRT in primary CNS lymphoma been settled?

Authors:  Lisa M DeAngelis
Journal:  Nat Rev Clin Oncol       Date:  2011-02-08       Impact factor: 66.675

4.  Isolated CNS Hodgkin's lymphoma: implications for tissue diagnosis.

Authors:  Derek L Martinez; Meena Gujrati; Francois Geoffroy; Andrew J Tsung
Journal:  CNS Oncol       Date:  2014-11

5.  BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.

Authors:  Keishi Makino; Hideo Nakamura; Naoki Shinojima; Jun-Ichiro Kuroda; Shigetoshi Yano; Yoshiki Mikami; Akitake Mukasa
Journal:  J Neurooncol       Date:  2018-07-02       Impact factor: 4.130

Review 6.  Conservative management of post-transplant central nervous system lymphoma.

Authors:  Shahul H Valavoor; Zubair Ashraf; Rawan Narwal; Shobha Ratnam
Journal:  Int Urol Nephrol       Date:  2012-04-03       Impact factor: 2.370

7.  Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens.

Authors:  Esteban Braggio; Ellen Remstein McPhail; William Macon; M Beatriz Lopes; David Schiff; Mark Law; Stephanie Fink; Debra Sprau; Caterina Giannini; Ahmet Dogan; Rafael Fonseca; Brian Patrick O'Neill
Journal:  Clin Cancer Res       Date:  2011-05-11       Impact factor: 12.531

Review 8.  The role of whole brain radiation in primary CNS lymphoma.

Authors:  Benjamin Kasenda; Jay Loeffler; Gerald Illerhaus; Andrés J M Ferreri; James Rubenstein; Tracy T Batchelor
Journal:  Blood       Date:  2016-05-13       Impact factor: 22.113

9.  Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report.

Authors:  Jaclyn J Renfrow; Alisha Detroye; Michael Chan; Stephen Tatter; Thomas Ellis; Kevin McMullen; Annette Johnson; Ryan Mott; Glenn J Lesser
Journal:  J Neurooncol       Date:  2012-01-17       Impact factor: 4.130

10.  Descriptive epidemiology of ophthalmic and ocular adnexal non-Hodgkin's lymphoma.

Authors:  Roxana Moslehi; F Bruce Coles; Maria J Schymura
Journal:  Expert Rev Ophthalmol       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.